hydroxychloroquine has been researched along with P carinii Pneumonia in 5 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Recurrences of COVID-19 were observed in a patient with long-term usage of hydroxychloroquine, leflunomide, and glucocorticoids due to her 30-year history of rheumatoid arthritis (RA)." | 5.05 | A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab. ( Cai, S; Dong, L; Li, M; Sun, W, 2020) |
| "001), and average oral dosage of >7." | 1.72 | Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan. ( Chang, YS; Chen, WS; Huang, YF; Lai, CC; Li, TH; Tsao, YP; Wang, WH, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yeo, KJ | 1 |
| Chen, HH | 1 |
| Chen, YM | 1 |
| Lin, CH | 1 |
| Chen, DY | 1 |
| Lai, CM | 1 |
| Chao, WC | 1 |
| Cai, S | 1 |
| Sun, W | 1 |
| Li, M | 1 |
| Dong, L | 1 |
| Quintana-Ortega, C | 1 |
| Remesal, A | 1 |
| Ruiz de Valbuena, M | 1 |
| de la Serna, O | 1 |
| Laplaza-González, M | 1 |
| Álvarez-Rojas, E | 1 |
| Udaondo, C | 1 |
| Alcobendas, R | 1 |
| Murias, S | 1 |
| Wang, WH | 1 |
| Lai, CC | 1 |
| Huang, YF | 1 |
| Li, TH | 1 |
| Tsao, YP | 1 |
| Chen, WS | 1 |
| Chang, YS | 1 |
| Podrebarac, TA | 1 |
| Jovaisas, A | 1 |
| Karsh, J | 1 |
1 review available for hydroxychloroquine and P carinii Pneumonia
| Article | Year |
|---|---|
A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
Topics: Aged; Anti-Bacterial Agents; Antifungal Agents; Antirheumatic Agents; Antiviral Agents; Arthritis, R | 2020 |
4 other studies available for hydroxychloroquine and P carinii Pneumonia
| Article | Year |
|---|---|
Hydroxychloroquine may reduce risk of Pneumocystis pneumonia in lupus patients: a Nationwide, population-based case-control study.
Topics: Adult; Antifungal Agents; Antirheumatic Agents; Case-Control Studies; Female; Glucocorticoids; Human | 2020 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2021 |
Pneumocystis Jirovecii Pneumonia in Systemic Lupus Erythematosus: A Nationwide Cohort Study in Taiwan.
Topics: Cohort Studies; Cyclophosphamide; Humans; Hydroxychloroquine; Kidney Failure, Chronic; Lupus Erythem | 2022 |
Pneumocystis carinii pneumonia after discontinuation of hydroxychloroquine in 2 patients with systemic lupus erythematosus.
Topics: Adult; Antirheumatic Agents; Drug Utilization; Female; Humans; Hydroxychloroquine; Lupus Erythematos | 1996 |